Cancer Treatment Results  Survival Rates Cancer Treatments / Therapy Results

Click here to go back to your search results.

Lung Cancer treatment details. Biologic therapy. Memorial Sloan-Kettering Cancer Center, New York, N.Y., United States

Survival: 9.5 months
Toxicity Grade: 3
Treatments: Biologic therapy
Country: United States
City/State/Province: New York, N.Y.
Hospital: Memorial Sloan-Kettering Cancer Center
Journal: Link
Date: 9/2006

Patients: This phase I/II trial involved 27 patients with advanced nonsmall cell lung cancer. The median age was 63, ranging from 39-82 years. Ten patients were women, 17 were men, and 5 had a history of smoking.

Treatment: Patients were treated with erlotinib (Tarceva), a kinase inhibitor.

Toxicity: No grade 4 toxicities were observed. Grade 1 and 2 rash and diarrhea were reported in 92% of patients. Grade 3 fatigue, pneumonitis, and dehydration were reported once. Other toxicities (grade 1 and 2) included nausea, weight loss, stomatits, and hyperbilirubinemia.

Results: The median survival for the 21 patients treated at the phase II dose was 9.5 months. The median time to progression was 1.7 months.

Support: This study was supported in part by Genentech, Inc, which developed and also supplied the erlotinib for the study.

Correspondence: Vincent A. Miller, M.D.

E-mail to a Friend Email Physician More Information